Mantle Cell Lymphoma Treatment Market is Projected to Reach US$ 5.77 Billion by 2034, with a 8.6% CAGR | Fact.MR Report

Need for Personalized Treatments Based on Genetic and Molecular Characteristics Driving Mantle Cell Lymphoma Treatment Market Expansion.

Rockville, MD, Aug. 15, 2024 (GLOBE NEWSWIRE) — According to a new industry report compiled by skilled analysts at Fact.MR, the Global Mantle Cell Lymphoma Treatment Market is projected to reach US$ 2.53 billion in 2024 and subsequently expand at a CAGR of 8.6% from 2024 to 2034.

The market for mantle cell lymphoma treatment has been projected to grow at a noteworthy pace over the coming years due to advancements in targeted therapies, immunotherapy, personalized medicine, global market expansion, and growing incidence rates globally. Some of the key happenings in the market include immunotherapy advancements, precision medicine, biomarker development, targeted therapies for specific pathways, combination therapies, and AI integration.

Mantle cell lymphoma (MCL) is a non-Hodgkin lymphoma (NHL) that affects the lymphatic system. The MCL treatment market is expected to evolve further as research and development progresses. Companies are focusing on developing more effective therapies to improve patient outcomes.

For More Insights into the Market, Request a Sample of this Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=10300

North America leads the global market by far, followed by Western Europe and East Asia; however, the market in South Asia & Pacific is expected to increase faster than those in all the other regions over the decade, with targeted therapy being most relied on across the world.

Key Takeaways from Market Study:

• The global market for mantle cell lymphoma treatment is projected to expand at a CAGR of 8.6% from 2024 to 2034.
• The market is forecasted to reach a value of US$ 5.77 billion by the end of 2034.
• The market in the United States is estimated at a value of US$ 899.1 million in 2024.
• India is projected to occupy a market share of 63.8% in the South Asia & Pacific region by 2034.
• Revenue from targeted therapy is forecasted to reach US$ 2.09 million by the end of 2034.
• The market in East Asia is analyzed to expand at a CAGR of 10.7% from 2024 to 2034.

“Advancements in genomics and molecular biology enable personalized treatment plans, driving the market for mantle cell lymphoma treatments,” says a Fact.MR analyst.

Leading Players Driving Innovation in the Mantle Cell Lymphoma Treatment Market:

F.Hoffman La Roche Ltd.; Abbvie, Inc.; Kite Pharma, Inc.; Bayer AG; Bristol-Myers Squibb Company; Celgene Corporation; Eli Lilly and Company; GlaxoSmithKline Plc; Amgen, Inc.; Gilead Sciences, Inc.; Johnson and Johnson; BeiGene; Beijing InnoCare Pharma Tech; Hutchison Medipharma; Acerta Pharma; AstraZeneca.

Strong Healthcare Research Infrastructure in United States:

Mantle cell lymphoma treatment is gaining popularity in the United States. The country leads the global market due to its strong research infrastructure, ongoing innovation in therapeutic approaches, widespread access to cutting-edge medical technologies, and a wide range of clinical trials conducted within the country.

Presence of world-renowned medical institutions, acclaimed oncologists, and collaborative efforts between academic and industrial sectors have all contributed to the United States’ position as a global leader in developing treatment options for mantle cell lymphoma.

Mantle Cell Lymphoma Treatment Industry News:

• In March 2023, China provisionally authorized AstraZeneca’s Calquence (acalabrutinib), a next-generation selective BTK inhibitor, for the treatment of adult patients with mantle cell lymphoma (MCL) who have had at least one prior therapy. In China, this is the first approved indication for Calquence.
• The oncology division of Loxo Lilly, an Eli Lilly and Company company, announced in January 2023 that Jaypirca, or pirtobrutinib, 100 mg and 50 mg tablets, was approved by the US Food and Drug Administration (FDA) to treat adult patients with relapsed or refractory mantle cell lymphoma (MCL) following at least two lines of systemic therapy, which included a BTK inhibitor.

Get Customization on this Report for Specific Research Solutions: https://www.factmr.com/connectus/sample?flag=S&rep_id=10300

More Valuable Insights on Offer:

Fact.MR, in its new offering, presents an unbiased analysis of the mantle cell lymphoma treatment market for 2019 to 2023 and forecast statistics for 2024 to 2034.

The study divulges insights into the mantle cell lymphoma treatment market based on therapy (chemotherapy, monoclonal antibody therapy, targeted therapy, radiotherapy, stem cell transplant), drug (zanubrutinib, ibrutinib, pirtobrutinib, nvg-111, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, bendamustine, HMPL-760, orelabrutinib, loxo-338), route of administration (oral, injectable), end-user (hospitals, specialty clinics, oncology research centers, rehabilitation centers, ambulatory surgical centers), and patient pool (pediatric, adult, geriatric), across seven major regions of the world (North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia & Pacific, and MEA).

Segmentation of MCL Treatment Market Research:

By Therapy:

• Chemotherapy
• Monoclonal Antibody Therapy
• Targeted Therapy
• Radiotherapy
• Stem Cell Transplant

By Drug:

• Zanubrutinib
• Ibrutinib
• Pirtobrutinib
• NVG-111
• Rituximab
• Cyclophosphamide
• Doxorubicin
• Vincristine
• Prednisone
• Bendamustine
• HMPL-760
• Orelabrutinib
• Loxo-338

By Route of Administration:

• Oral
• Injectable

By End User:

• Hospitals
• Specialty Clinics
• Oncology Research Centers
• Rehabilitation Centers
• Ambulatory Surgical Centers

By Patient Pool:

• Pediatric
• Adult
• Geriatric

Check out More Related Studies Published by Fact.MR Research:

Cancer Immunotherapy Market: is projected to increase at a CAGR of 10% and reach a market value of US$ 412.8 billion by 2034.

Cancer Biomarker Market: is expected to exceed US$ 34 Billion by 2032, representing a threefold increase from 2022. The market is currently worth slightly more than US$ 11 Billion. During the forecasted period, the global market for cancer biomarkers is estimated to grow at an incredible 12% CAGR.

Cancer Profiling Market: is expected to yield significant gains across 2021, as preference for precision-based medicine and high-quality oncology care acquires increasing traction.

Cancer Supportive Care Product Market: is projected to increase from a value of US$ 35.47 billion in 2024 to US$ 68.93 billion by the end of 2034. 

Monoclonal Antibodies Market: size is valued at US$ 228.99 billion in 2023 and is forecasted to reach US$ 692.39 billion, expanding swiftly at a CAGR of 11.7% through 2033.

About Us:

Fact.MR is a distinguished market research company renowned for its comprehensive market reports and invaluable business insights. As a prominent player in business intelligence, we deliver deep analysis, uncovering market trends, growth paths, and competitive landscapes. Renowned for its commitment to accuracy and reliability, we empower businesses with crucial data and strategic recommendations, facilitating informed decision-making and enhancing market positioning.

With its unwavering dedication to providing reliable market intelligence, FACT.MR continues to assist companies in navigating dynamic market challenges with confidence and achieving long-term success. With a global presence and a team of experienced analysts, FACT.MR ensures its clients receive actionable insights to capitalize on emerging opportunities and stay competitive.

Contact:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Sales Team: [email protected]
Follow Us: LinkedIn | Twitter | Blog